
Bioorganic and Medicinal Chemistry Letters p. 853 - 856 (1999)
Update date:2022-08-05
Topics:
Vince, Robert
Brownell, Jay
Akella, Lakshmi B.
The inhibition of glyoxalase I enzyme to increase cellular levels of methylglyoxal has been developed as a rationale for the production of anticancer agents. Synthesis of a peptidomimetic analog of the previously prepared potent glyoxalase inhibitor, S-(p-bromobenzyl)glutathione (PBBG), was accomplished by inserting a urea linkage, NH-CO-NH, to replace the γ- glutamyl peptide bond. Thus, the target compound, γ-(L-γ-azaglutamyl)-S- (p-bromobenzyl)-L-cysteinylglycine 6, was a potent inhibitor of glyoxalase I with almost no loss of activity when compared to PBBG. However, unlike PBBG, 6 was completely resistant to enzymatic degradation by kidney homogenate or by purified γ-glutamyltranspeptidase enzyme.
View MoreTianjin Te-An Chemtech Co., Ltd.(expird)
Contact:+86-22-65378638
Address:A5-8, No.80 Haiyun Street, TEDA
Hangzhou Hysen Pharma co.,Ltd.
website:http://www.hysenpharma.cn/
Contact:0086-571-88298791
Address:#701,Gudun Road Hangzhou
Contact:+86-532-80762375
Address:No. 6, Hongkong Middle Road, Qingdao, China
Henan Yellow River New Material Technology Co.Ltd.
website:http://www.yellowriverchem.com
Contact:0086-373-7278760
Address:Chengguan Town, Yuanyang County
Henan Yellow River New Material Technology Co.Ltd.
website:http://www.yellowriverchem.com
Contact:0086-373-7278760
Address:Chengguan Town, Yuanyang County
Doi:10.1016/j.tet.2013.10.024
(2013)Doi:10.1055/s-2001-18706
(2001)Doi:10.1016/S0022-328X(00)86348-2
(1968)Doi:10.1021/ic50075a007
(1969)Doi:10.1016/S0040-4039(01)88000-X
(1969)Doi:10.1021/om990023q
(1999)